BenevolentAI
with the world attention on applications that deliver real world impact we are strongly positioned to on this moment with our substantial portfolio of platform generated drugs our work with big and research collaborators and our continued investment in state of the art technology we are showing every day how can be used to unlock the next wave of innovation shields poised for growth multiple value in points expected ben top line results of the phase clinical trial expected in out license in subject to results ben initiate the phase i study in ben submit the in continued investment in state of the art technology aim to sign additional commercial collaboration commence enabling studies for at least one additional asset continue to progress pipeline assets to value in points | BenevolentAI
Company
Deck Type
Deck date
March 2023
Slide
23 of 38
Related slides by other companies
Investor Day
March 2022
Investor Presentation
January 2024
Investor Presentation
March 2023
Investor Presentation
August 2023
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Investor Conference
January 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io